+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comprehensive analysis of PTEN status in Sezary syndrome



Comprehensive analysis of PTEN status in Sezary syndrome



Blood 122(20): 3511-3520



Sézary syndrome (SS) is an incurable leukemic variant of cutaneous T-cell lymphoma characterized by recurrent chromosomal alterations, among which, chromosome 10q deletion is very frequent. In this study, we investigated the PTEN status, on locus 10q23, in 44 SS patients; our findings show that PTEN is deleted in 36% of SS cases, whereas PTEN downregulation is observed in almost all of the samples evaluated by quantitative reverse-transcriptase polymerase chain reaction and Western blotting analysis. Neither DNA sequence mutation nor promoter hypermethylation were found at the PTEN locus, but we demonstrate that PTEN level can be also reduced by a group of miRs previously found upregulated and of prognostic relevance in SS; particularly, miR-21, miR-106b, and miR-486 were able to control PTEN abundance either in vitro or in vivo. Finally, because reduced PTEN activates the PI3/AKT-mediated pathway of cell growth and survival, we demonstrate that PTEN deficiency is associated with activated AKT in skin resident but not circulating SS cells, suggesting that the cutaneous milieu may strongly contribute to the SS cell growth. To our knowledge, this is the first study fully exploring the PTEN status in a large cohort of SS patients, unveiling potential elements of clinical utility in this malignancy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052269710

Download citation: RISBibTeXText

PMID: 24062018

DOI: 10.1182/blood-2013-06-510578


Related references

Comprehensive analysis of PTEN status in breast carcinomas. International Journal of Cancer 133(2): 323-334, 2013

Germline PTEN Mutation Analysis for PTEN Hamartoma Tumor Syndrome. Methods in Molecular Biology 1388: 63-73, 2016

Establishment and characterization of continuous sezary cell lines from patients with sezary syndrome. Clinical Research 35(3): 693A, 1987

The Sézary syndrome: cytogenetic studies and identification of the Sézary Cell as an abnormal lymphocyte. American Journal of Medicine 50(1): 24-34, 1971

Circulating sezary cells in the diagnosis of sezary syndrome quantitative and morphometric analyses. Journal of Investigative Dermatology 81(4): 315-319, 1983

The man behind the eponym dermatology in historical perspective: Albert Sézary and the Sézary syndrome. American Journal of Dermatopathology 28(4): 357-367, 2006

A novel mouse model for Sezary Syndrome using xenotransplantation of Sezary cells into immunodeficient RAG2-/- ?c-/- mice. 2012

A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) mice. Experimental Dermatology 21(9): 706-709, 2013

Morphocytochemical characteristics of Sézary cells in the erythrodermic form of mycosis fungoides and Sézary syndrome. Sovetskaia Meditsina: 43-47, 1986

Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab?. Journal of the American Academy of Dermatology 67(5): 1083-1085, 2013

Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. Blood 120(16): 3288-3297, 2013

Loss of sezary cell suppressor activity in sezary syndrome with progressive lymph node disease. Clinical Research: 313a, 1980